Download PDF
Nuklearmedizin 2022; 61(05): 416-417
DOI: 10.1055/a-1856-4290
Case Report

Successful PRRT-rechallenge in a metastasized neuroendocrine tumor of the middle ear

Erfolgreiche Rechallenge-PRRT eines metastasierten neuroendokrinen Tumors des Mittelohrs
Juri Ruf
1   Klinik für Nuklearmedizin, Universitätsklinikum Freiburg, Freiburg, Germany (Ringgold ID: RIN14879)
,
Christoph Becker
2   Klinik für Hals-, Nasen- und Ohrenheilkunde, Medizinische Fakultät, Universität Freiburg, Freiburg, Gemany
,
Philippe Dovi-Akué
3   Klinik für Neuroradiologie, Universitätsklinikum Freiburg, Freiburg
,
Volker Brass
4   Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Freiburg
,
Steffen Heeg
4   Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Freiburg
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Introduction

Commonly neuroendocrine tumors (NET) oft the middle ear are regarded as benign pathologies [1]. We present the case of a patient who not only suffered from repetitive local recurrences but also developed systemic metastases successfully treated by repeated peptide-receptor radionuclide-therapy (PRRT).



Publication History

Received: 26 January 2022

Accepted after revision: 12 May 2022

Article published online:
18 August 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Torske KR, Thompson LD. Adenoma versus carcinoid tumor of the middle ear: a study of 48 cases and review of the literature. Mod Pathol 2002; 15 (05) 543-555
    CrossrefPubMedSearch in Google Scholar
  • 2 Ratnayake GM, Luong TV, Toumpanakis C. et al. Middle ear neuroendocrine tumours: Insight into their pathogenesis, diagnosis and management. J Neuroendocrinol 2021; 33 (09) e13031
    CrossrefPubMedSearch in Google Scholar
  • 3 Saliba I, Evrard AS. Middle ear glandular neoplasms: adenoma, carcinoma or adenoma with neuroendocrine differentiation: a case series. Cases J 2009; 02: 6508
    CrossrefPubMedSearch in Google Scholar
  • 4 Strosberg J, El-Haddad G, Wolin E. et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 376 (02) 125-135
    CrossrefPubMedSearch in Google Scholar
  • 5 Lima Ferreira J, Marques B, Menke-van der Houven van Oordt CW. et al. Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features. Endocrinol Diabetes Metab Case Rep 2021; 20–0172
    CrossrefPubMedSearch in Google Scholar
  • 6 Rudisile S, Gosewisch A, Wenter V. et al. Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. BMC Cancer 2019; 19 (01) 788
    CrossrefPubMedSearch in Google Scholar